Sunil Parimi

620 total citations
18 papers, 142 citations indexed

About

Sunil Parimi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Sunil Parimi has authored 18 papers receiving a total of 142 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 4 papers in Surgery. Recurrent topics in Sunil Parimi's work include Prostate Cancer Treatment and Research (10 papers), Cancer Genomics and Diagnostics (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Sunil Parimi is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Cancer Genomics and Diagnostics (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Sunil Parimi collaborates with scholars based in Canada, Finland and United States. Sunil Parimi's co-authors include Kim N., Jose Gerard Monzon, Patricia A. Tang, Joanna Vergidis, Katherine Sunderland, Vincent C. Tam, Bernhard J. Eigl, Jenny J. Ko, Erica S. Tsang and Roger Y. Tsang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Sunil Parimi

16 papers receiving 142 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sunil Parimi Canada 7 91 57 44 37 26 18 142
Alina Fuerea France 8 93 1.0× 86 1.5× 24 0.5× 65 1.8× 37 1.4× 28 167
Elvira Buxó Spain 8 111 1.2× 64 1.1× 28 0.6× 39 1.1× 45 1.7× 17 180
Marie-Paule Sablin France 4 45 0.5× 63 1.1× 31 0.7× 24 0.6× 43 1.7× 4 135
Xiangpeng Chu China 8 105 1.2× 48 0.8× 32 0.7× 30 0.8× 45 1.7× 26 191
Jessica Burns United Kingdom 7 84 0.9× 48 0.8× 23 0.5× 25 0.7× 31 1.2× 15 158
Paula Peleteiro Spain 6 102 1.1× 35 0.6× 83 1.9× 38 1.0× 70 2.7× 8 191
O. B. Kаryakin Russia 5 68 0.7× 43 0.8× 29 0.7× 28 0.8× 43 1.7× 29 105
J. De Langen Netherlands 7 99 1.1× 124 2.2× 32 0.7× 22 0.6× 28 1.1× 18 159
Yakup Ergün Türkiye 7 58 0.6× 122 2.1× 19 0.4× 62 1.7× 30 1.2× 44 181
Jesús Corral Jaime Spain 8 114 1.3× 108 1.9× 21 0.5× 18 0.5× 53 2.0× 15 178

Countries citing papers authored by Sunil Parimi

Since Specialization
Citations

This map shows the geographic impact of Sunil Parimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunil Parimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunil Parimi more than expected).

Fields of papers citing papers by Sunil Parimi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunil Parimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunil Parimi. The network helps show where Sunil Parimi may publish in the future.

Co-authorship network of co-authors of Sunil Parimi

This figure shows the co-authorship network connecting the top 25 collaborators of Sunil Parimi. A scholar is included among the top collaborators of Sunil Parimi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunil Parimi. Sunil Parimi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Schönlau, Elena, David C. Müller, Gillian Vandekerkhove, et al.. (2023). Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.. Journal of Clinical Oncology. 41(16_suppl). 4577–4577.
2.
Ko, Jenny J., Julia Adams, Katherine Sunderland, et al.. (2022). Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate. Canadian Urological Association Journal. 16(11). E528–E532. 2 indexed citations
3.
Parimi, Sunil, Katherine Sunderland, François Bachand, et al.. (2020). Presenting Stage and Risk Group in Men Dying of Prostate Cancer. Current Oncology. 27(6). 547–551. 2 indexed citations
4.
Tsang, Erica S., Connor M. Forbes, K. N., Bernhard J. Eigl, & Sunil Parimi. (2019). Second-Line Systemic Therapies for Metastatic Urothelial Carcinoma: A Population-Based Cohort Analysis. Current Oncology. 26(2). 260–265. 3 indexed citations
5.
Parimi, Sunil, Erica S. Tsang, Michael McKenzie, et al.. (2018). Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer. Canadian Urological Association Journal. 13(10). E311–6. 4 indexed citations
6.
Chedgy, Edmund C.P., Gillian Vandekerkhove, Cameron Herberts, et al.. (2018). Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma. The Journal of Pathology. 246(2). 244–253. 34 indexed citations
7.
Parimi, Sunil, Erica S. Tsang, Abraham Alexander, et al.. (2017). A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion. Canadian Urological Association Journal. 11(10). 350–5. 17 indexed citations
8.
Parimi, Sunil & Jenny J. Ko. (2017). Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review. Expert Review of Anticancer Therapy. 17(10). 939–949. 6 indexed citations
9.
Nixon, Nancy, Omar Khan, Patricia A. Tang, et al.. (2017). Drug development for breast, colorectal, and non–small cell lung cancers from 1979 to 2014. Cancer. 123(23). 4672–4679. 17 indexed citations
10.
11.
Ezeife, Doreen A., Sunil Parimi, Tony H. Truong, et al.. (2017). The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value. Journal of the National Comprehensive Cancer Network. 15(8). 1005–1013.
12.
Parimi, Sunil, Misha Eliasziw, Scott North, et al.. (2016). Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). Investigational New Drugs. 34(6). 771–776. 3 indexed citations
14.
Parimi, Sunil & Kim N.. (2016). Chemotherapy for metastatic castration‐sensitive prostate cancer. International Journal of Urology. 23(9). 726–733. 12 indexed citations
15.
Wyatt, Alexander W., Matti Annala, Sunil Parimi, et al.. (2016). Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). 5034–5034. 2 indexed citations
16.
Parimi, Sunil, Bernhard J. Eigl, Katherine Sunderland, et al.. (2016). Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). 5059–5059. 9 indexed citations
17.
Parimi, Sunil, et al.. (2015). Trends in the design and interpretation of metastatic colorectal cancer phase III clinical trials.. Journal of Clinical Oncology. 33(3_suppl). 692–692. 13 indexed citations
18.
Parimi, Sunil & Roger Y. Tsang. (2014). Hsp90 Inhibitors in Oncology: Ready for Prime Time?. Current Oncology. 21(5). 663–667. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026